Fundamental analysis of $ALZN (Alzamend Neuro, Inc.) based on financial data and reported results.

#ALZN

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital Alzamend Neuro (Nasdaq: ALZN) announced completion of the clinical portion of its Phase II study of AL001 in healthy subjects on Nov 19, 2025. The study compared lithium blood and brain pharmacokinetics of AL001 versus a marketed lithium carbonate product using a proprietary high-resolution whole-brain lithium imaging head coil from Tesla Dynamic Coils BV.Topline data are expected in Q1 2026. Company says results will inform planned Phase II trials in Alzheimer's, bipolar disorder, major depressive disorder, and PTSD next year; prior mouse studies reportedly showed higher brain uptake with lower blood lithium levels.

#ALZN Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs Alzamend Neuro (Nasdaq: ALZN) reported its annual financial results for FY2025 and provided updates on its clinical programs. The company significantly improved its financial position with stockholder equity reaching $4.0 million and cash holdings of $3.9 million as of April 30, 2025. In June 2025, Alzamend completed a $5 million private placement ahead of schedule.The company's lead candidate AL001, a lithium-based treatment for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD, began the first of five Phase II trials at Massachusetts General Hospital in May 2025. Their second candidate, ALZN002, an immunotherapy treatment for Alzheimer's, faced delays after their CRO terminated the agreement in February 2024, and the company is seeking a new partner to continue the Phase I/IIA trial.

#ALZN Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

www.stocktitan.net/news/ALZN/alzamend-neuro...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu May 29th - #RIG #JBLU #EOSE #ALZN #NVTS #ZEO #VLRS #SBET #QUBT #KULR #IMNN #HOLO #HL #HBIO #DAVE #CLF #BTCS #AI #AEO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping up in trading, Thu May 29th - #WETO #STRM #ZEO #SVT #TALK #ORIC #LZMH #BOSC #EXPI #ALZN #DDC #BBW - More: crystalequityresearch.com/SmCpStr/ - #smallcap

News; ( NASDAQ: #ALZN ) PRISM Mid-Day Movers: Lithium Treatment Innovation and Feeding Tube Tech Fuel Index Gains

JUST IN: ( NASDAQ: #ALZN ) Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs

PRISM Mid-Day Movers:
#AlzamendNeuro , Inc. ( #ALZN) soared 72%,
#nanovibronix , Inc. ( #NAOV) advanced 43%,
prismmarketview.com/prism-mid-da...

News; ( NASDAQ: #ALZN ) BioMedNewsBreaks - Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001

Breaking News: ( NASDAQ: #ALZN ) Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital Alzamend Neuro, Inc. (Nasdaq:

#ALZN Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital Alzamend Neuro, Inc. (Nasdaq:

#ALZN Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

Alzamend Neuro Advances Alzheimer’s Drug Candidate into Phase II Trial Alzamend Neuro (ALZN) announced the initiation of a Phase II clinical trial for AL001, its lead drug candidate targeting mild to moderate Alzheimer’s disease.

#ALZN launches Phase II trial for AL001, a novel Alzheimer’s drug targeting disease modification and symptom relief. With FDA Fast Track status, it aims to address unmet needs for 6M+ patients.
#AlzamendNeuro #Alzheimers #Biotech #ClinicalTrials
Read more: prismmarketview.com/alzamend-neu...

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital Alzamend Neuro (NASDAQ: ALZN) has initiated its first of five Phase II clinical trials for AL001, a novel lithium-based treatment, at Massachusetts General Hospital. The study will compare AL001 with marketed lithium carbonate to evaluate brain and blood pharmacokinetics in healthy subjects, with topline data expected by year-end.AL001 represents a potential breakthrough in lithium treatment, showing better brain absorption while maintaining lower blood levels in previous mouse studies. The drug aims to eliminate the need for therapeutic drug monitoring (TDM), addressing a major limitation of current lithium treatments. This advancement could benefit over 43 million Americans affected by Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD.

#ALZN Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

Breaking News: ( NASDAQ: #ALZN ) ALZN announced stock split 1-9

Alzamend Neuro Announces Reverse Stock Split Alzamend Neuro (NASDAQ: ALZN) has announced a 1-for-9 reverse stock split effective May 12, 2025. The clinical-stage biopharmaceutical company, focused on developing treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD, implemented this measure primarily to maintain Nasdaq listing compliance with the minimum bid requirement of $1.00 per share.The company's outstanding shares will decrease from approximately 7,208,591 to 800,954 shares. The stock will continue trading under the symbol "ALZN" with a new CUSIP number 02262M605. While the split affects all issued and outstanding shares, including equity incentive plans and outstanding options/warrants, it won't alter stockholders' percentage ownership. Stockholders entitled to fractional shares will receive cash payments instead.

#ALZN Alzamend Neuro Announces Reverse Stock Split

www.stocktitan.net/news/ALZN/alzamend-neuro...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Wed May 7th - #WRD #SYTA #OKYO #KAVL #SNCR #MYGN #LFVN #HAIN #GDRX #YAAS #ARIS #BGS #EPC #GFR #MAGN #RVLV #VSTS #ALZN #BNR #CEVA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital Alzamend Neuro (NASDAQ: ALZN) has partnered with QMENTA, an AI medical imaging company, to support five upcoming Phase II clinical trials of AL001 at Massachusetts General Hospital. The trials will compare AL001 to marketed lithium carbonate, focusing on lithium blood and brain pharmacokinetics in healthy subjects. AL001 aims to deliver lithium more effectively to the brain while maintaining lower blood levels, potentially eliminating the need for therapeutic drug monitoring. Previous mouse studies showed improved brain absorption with reduced systemic exposure. The partnership leverages QMENTA's cloud-based platform for managing and analyzing medical imaging data, ensuring regulatory compliance and operational efficiency. This collaboration targets treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. The study aims to demonstrate AL001's targeted effectiveness and reduced side effects compared to traditional lithium salts, which require frequent monitoring due to narrow therapeutic windows.

#ALZN Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital Advanced lithium-based treatment shows superior brain absorption with reduced side effects. Phase II trial at Mass General to validate breakthrough approach. Full analysis inside.

#ALZN Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital Alzamend's AL001 advances to Phase II trials for major depression, promising better brain absorption with reduced monitoring needs. Mass General Hospital to lead groundbreaking study.

#ALZN Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

Can This New Lithium Formulation Revolutionize Bipolar Disorder Treatment? Alzamend's Phase II Trial Targets 7M+ Patients AL001 aims to eliminate monitoring requirements while delivering better brain absorption than traditional lithium treatments for 7+ million Americans with bipolar disorder.

#ALZN Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital Alzamend Neuro (NASDAQ: ALZN) has announced plans to initiate the first of five phase II clinical studies for AL001 in the second quarter of 2025. The initial study will be conducted at Massachusetts General Hospital with healthy human subjects following the successful development of a novel head coil by Tesla Dynamic Coils BV.This head-to-head study will compare AL001 with marketed lithium carbonate products, focusing on lithium blood and brain pharmacokinetics. Previous mouse studies showed AL001 provides better brain absorption while maintaining lower blood lithium levels, potentially eliminating the need for therapeutic drug monitoring (TDM).AL001 aims to overcome limitations of current FDA-approved lithium salts (carbonate and citrate), which require regular monitoring due to narrow therapeutic windows and multiple daily doses. The novel formulation could represent a significant advancement in treating Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD by reducing kidney and thyroid side effects associated with traditional lithium therapies.

#ALZN Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

www.stocktitan.net/news/ALZN/alzamend-neuro...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Wed Feb 19th - #WOOF #XOS #CHCT #DEC #FVRR #JELD #MBC #UIC #ALZN #BMBL #CMMB #LNKB #NEXN #PERI #SBLK #TCMD #VACH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Alzamend Neuro Secures $25M Financing Deal, Advances Alzheimer's Drug Pipeline Amid Financial Turnaround Biotech firm strengthens balance sheet with major financing deals, boosts equity to $3.8M, and prepares for important Alzheimer's drug trials in 2025 at Mass General Hospital.

#ALZN Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

#StockMarket #investing #stocks

www.stocktitan.net/news/ALZN/alzamend-neuro...

News; ( NASDAQ: #ALZN ) Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #ALZN ) Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next?Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

#StockMarket #News

NEWS: ( NASDAQ: #ALZN ) Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next?Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

#StockMarket #News

News; ( NASDAQ: #ALZN ) Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer's Disease

#StockMarket #News